Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

被引：0
|
作者：
Yutaka Fujiwara
Hiroshi Nokihara
Yasuhide Yamada
Noboru Yamamoto
Kuniko Sunami
Hirofumi Utsumi
Hiroya Asou
Osamu TakahashI
Ken Ogasawara
Ivelina Gueorguieva
Tomohide Tamura
机构：
[1] National Cancer Center Hospital,Department of Thoracic Oncology
[2] National Cancer Center Hospital,Gastrointestinal Oncology
[3] Eli Lilly Japan K.K.,Medical Science
[4] Eli Lilly Japan K.K.,Japan PK/PD
[5] Lilly Research Laboratories,Global PK/PD
[6] The Jikei University School of Medicine,Respiratory Medicine
[7] St Luke’s International Hospital,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 76卷
关键词：
Galunisertib; LY2157299; Pharmacokinetics; Safety; TGF-beta;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1143 / 1152
页数：9
相关论文
共 50 条
  • [1] Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors
    Fujiwara, Yutaka
    Nokihara, Hiroshi
    Yamada, Yasuhide
    Yamamoto, Noboru
    Sunami, Kuniko
    Utsumi, Hirofumi
    Asou, Hiroya
    Takahash, Osamu, I
    Ogasawara, Ken
    Gueorguieva, Ivelina
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1143 - 1152
  • [2] Preclinical Efficacy of TGF-Beta Receptor I Kinase Inhibitor, Galunisertib, in Myelofibrosis
    Yue, Lanzhu
    Bartenstein, Matthias
    Zhao, Wanke
    Ho, Wan-Ting
    Zhang, Ling
    Rapaport, Franck
    Levine, Ross L.
    Shao, Zonghong
    Zhao, Zhizhuang Joe
    Verma, Amit
    Epling-Burnette, Pearlie K
    BLOOD, 2015, 126 (23)
  • [3] POPULATION PHARMACOKINETICS OF A NOVEL TGF-BETA RECEPTOR I KINASE INHIBITOR VACTOSERTIB IN PATIENTS WITH ADVANCED-STAGE SOLID TUMORS.
    Lee, J. I.
    Jung, S. Y.
    Yug, J. S.
    Chung, E. K.
    Keedy, V. L.
    Bauer, T. M.
    Clarke, J. M.
    Hurwitz, H.
    Lee, H.
    Park, N.
    Lee, S.
    Kim, H. -K.
    Baek, I.
    Hwang, S.
    Nam, S. Y.
    Ha, I.
    Kim, S. -J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S103 - S103
  • [4] A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
    Shinji Nakamichi
    Hiroshi Nokihara
    Noboru Yamamoto
    Yasuhide Yamada
    Kazunori Honda
    Yosuke Tamura
    Hiroshi Wakui
    Tatsuya Sasaki
    Wataru Yusa
    Katsuki Fujino
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1153 - 1161
  • [5] A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
    Nakamichi, Shinji
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Honda, Kazunori
    Tamura, Yosuke
    Wakui, Hiroshi
    Sasaki, Tatsuya
    Yusa, Wataru
    Fujino, Katsuki
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1153 - 1161
  • [6] A phase I study of a TGF-β receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors.
    Li, Jin
    Liu, Tianshu
    Bao, Hanying
    Xu, Zusheng
    Shu, Yang
    Zheng, Binghua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
    Kelley, R. K.
    Gane, E.
    Assenat, E.
    Siebler, J.
    Galle, P. R.
    Merle, P.
    Hourmand, I. O.
    Cleverly, A.
    Zhao, Y.
    Gueorguieva, I
    Lahn, M.
    Faivre, S.
    Benhadji, K. A.
    Giannelli, G.
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2019, 10
  • [8] DISSECTING THE MOLECULAR ANTIFIBROTIC EFFECT OF THE TGF-BETA(I) RECEPTOR KINASE INHIBITOR GALUNISERTIB IN PRECISION-CUT LIVER SLICES
    Luangmonkong, T.
    Suriguga, S.
    Bigaeva, E.
    Oosterhuis, D.
    de Jong, K.
    Schuppan, D.
    Mutsaers, H.
    Olinga, P.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S713 - S714
  • [9] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Hideki Ueno
    Shunsuke Kondo
    Shusuke Yoshikawa
    Koichi Inoue
    Valérie Andre
    Masaomi Tajimi
    Haruyasu Murakami
    Investigational New Drugs, 2018, 36 : 647 - 656
  • [10] A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors
    Ueno, Hideki
    Kondo, Shunsuke
    Yoshikawa, Shusuke
    Inoue, Koichi
    Andre, Valerie
    Tajimi, Masaomi
    Murakami, Haruyasu
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 647 - 656
12345